Scientific deep-dive

CagriSema Beat Semaglutide. By How Much?

CagriSema was statistically superior to semaglutide on HbA1c in type 2 diabetes. The margin was 0.16 percentage points, and adverse events were higher: 86.9% against 81.2%.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·8 citations

CagriSema, semaglutide combined with cagrilintide, met its endpoint against semaglutide alone in people with type 2 diabetes, and the result is fairly reported as superiority. The margin, though, is 0.16 percentage points of HbA1c, and adverse events were more common in the combination group.[1]

What was actually measured

REIMAGINE 2 compared CagriSema against semaglutide and against cagrilintide alone in adults with type 2 diabetes already taking metformin, with or without an SGLT2 inhibitor. The endpoint was HbA1c, a measure of blood sugar control, not weight.

Change in HbA1c, in percentage points. From the published report.
GroupHbA1c changeAdverse events
CagriSema (2.4 mg each)−1.91524 of 603 (86.9%)
Semaglutide 2.4 mg−1.75491 of 605 (81.2%)
Difference−0.16 (95% CI −0.27 to −0.05), p=0.0035+5.7 points

So the combination lowered HbA1c by about a sixth of a percentage point more than semaglutide alone, while roughly six more people in every hundred reported an adverse event. Gastrointestinal effects were the most common in every active group.[1]

Why 'superior' is a technical word

In trial language, superiority means the confidence interval excludes zero in the right direction. It carries no information about size. A large enough trial can establish superiority for a difference too small for any patient to notice, and that is roughly what happened here.

Superior, in this trial, means 0.16 percentage points of HbA1c.

Whether 0.16 points of HbA1c matters depends entirely on where you are starting. For someone close to target it is negligible. For someone far above it, on a drug they already tolerate, it is still unlikely to be the deciding factor, and the extra adverse events weigh against it.

This was not the weight trial, and that is the mistake to avoid. CagriSema is being developed principally as an obesity treatment, and coverage of this result will be read as though it were about weight. It was about blood sugar in people with type 2 diabetes on metformin. The weight answers come from other trials. Against placebo, REDEFINE 1 recorded −20.4% against −3.0% over 68 weeks.[3] Against tirzepatide 15 mg, the open-label REDEFINE 4 missed its primary endpoint: CagriSema failed to show it was non-inferior, losing 20.2% against 23.6% at 84 weeks.[4]

What the combination is trying to do

Cagrilintide is an amylin analog (one of several now in trials, alongside eloralintide and petrelintide), a different mechanism from a GLP-1. The logic of combining them is the same as pairing drugs in oncology or hypertension: two pathways, additive effect, potentially lower doses of each. It is a reasonable strategy, and the field is clearly moving toward it (see also bimagrumab plus semaglutide).

Cagrilintide is also on the FDA’s list of molecules that cannot lawfully be used in compounding. Anything offering a CagriSema-style combination outside a trial is built on that listed molecule, not an early look at a coming drug.

Two more trials, and the one that answers the real question

REIMAGINE 1 tested the combination in 189 people with type 2 diabetes managing it with diet and exercise alone. At 40 weeks, HbA1c fell 1.8 percentage points on the higher dose against 0.1 on placebo, and weight fell 13.8% against 1.4%.[2] Against a placebo, in people not yet taking any diabetes medicine, those are best-case conditions for the combination in type 2 diabetes.

The trial worth more than either is the one with an active comparator. REDEFINE 5 randomized 331 people to the combination or to semaglutide alone, which is the only comparison that answers what someone already taking semaglutide wants to know. The combination won by 6.5 percentage points, with gastrointestinal side effects essentially unchanged, which almost nothing in this field manages.[6] We take that apart in more effect without more side effects.

Two later trials tested it against tirzepatide in type 2 diabetes, and so far only the company has reported them. In the open-label REIMAGINE 4, at 68 weeks and assuming everyone stayed on treatment, CagriSema 2.4 mg lowered weight by 15.2% against 15.8% on tirzepatide 15 mg, which counted as non-inferior, and HbA1c by 1.9 points against 2.2, which did not.[7] REIMAGINE 5 used lower doses of both. At week 60, on the same assumption, CagriSema 1.0 mg lowered weight by 12.4% against 9.1% on tirzepatide 5 mg, which Novo calls superior, with HbA1c down 1.71 and 1.67 points, which it calls non-inferior.[8] So the answer to “does it beat tirzepatide” depends on the dose matched against it.

Novo filed CagriSema with the FDA in December 2025.[5] As of November 1, 2026, no FDA decision had been announced; Novo says it expects one in the fourth quarter of 2026.[8] It is not approved.

Frequently Asked Questions

On blood sugar in people with type 2 diabetes, statistically yes and marginally. HbA1c fell 1.91 percentage points against 1.75, a difference of 0.16 points, while adverse events were reported by 86.9% against 81.2%.
No. Superiority in trial language means the difference is unlikely to be chance. It says nothing about size, and a large trial can establish superiority for a difference too small to notice.
No. This trial measured HbA1c in people with type 2 diabetes taking metformin, with or without an SGLT2 inhibitor. The weight trials are separate. REDEFINE 1 recorded 20.4% against 3.0% on placebo over 68 weeks. Against tirzepatide 15 mg, REDEFINE 4 missed its primary endpoint, with 20.2% against 23.6% at 84 weeks.
Novo reports that in REIMAGINE 4, CagriSema 2.4 mg lowered HbA1c 1.9 points against 2.2 on tirzepatide 15 mg and missed non-inferiority, while weight loss was 15.2% against 15.8%. At lower doses in REIMAGINE 5, CagriSema 1.0 mg took off 12.4% against 9.1% on tirzepatide 5 mg. Neither trial has been published.
An amylin analog, which works by a different mechanism from a GLP-1. Combining the two aims to hit two pathways at once, which is the same logic used for combination therapy in other fields.
No. Cagrilintide is one of the molecules the FDA says cannot be used in compounding under federal law, and it is not a component of any approved drug. Anything sold as a compounded CagriSema equivalent is outside that rule.

References

  1. 1.Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study The Lancet Diabetes & Endocrinology. 2026. PMID: 42251859.
  2. 2.Aroda VR, Buzzetti R, Dalskov SM, et al. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study The Lancet Diabetes & Endocrinology. 2026. PMID: 42251860.
  3. 3.Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine. 2025. PMID: 40544433.
  4. 4.Novo Nordisk A/S CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved (Form 6-K) U.S. Securities and Exchange Commission, February 23, 2026. 2026. https://www.sec.gov/Archives/edgar/data/353278/000117184326000996/f6k_022326.htm
  5. 5.Novo Nordisk Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management PR Newswire, December 18, 2025. 2025. https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
  6. 6.Yamauchi T, Becker NP, Hagemann CA, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial The Lancet Diabetes & Endocrinology. 2026. PMID: 42009015.
  7. 7.Novo Nordisk A/S Financial report for the first six months of 2026 (Form 6-K), REIMAGINE 4 entry U.S. Securities and Exchange Commission, August 4, 2026. 2026. https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm
  8. 8.Novo Nordisk A/S Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial Novo Nordisk news release, September 21, 2026. 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916774

Bimagrumab Plus Semaglutide: The Muscle Question

The combination lost 17.8 kg at 48 weeks against 14.2 kg for semaglutide alone. But bimagrumab exists to change what you lose, and the published summary reports only how much.

6 min read

Eloralintide and Petrelintide: The Amylin-Only Drugs in Phase 3

In phase 2, Lilly's eloralintide cut weight by about 20% at 48 weeks; Zealand and Roche's petrelintide up to 10.7% at 42 weeks with little vomiting. Both are in phase 3, due to finish in 2028. Neither is approved.

10 min read

Elecoglipron: A Second Oral GLP-1 Pill in Phase 2

Weight reductions from 2.6% to 10.5% at 26 weeks depending on dose, against 0.6% on placebo. 93% completed the study but only 75% completed the assigned treatment.

5 min read

Cagrilintide: What the Evidence Shows, and Why You Can't Buy It

Cagrilintide, Novo Nordisk's amylin analog, produced 11.8% weight loss on its own at 68 weeks, less than semaglutide. It is not approved, cannot be compounded, and FDA has warned companies selling it.

9 min read

A Drug to Protect Muscle

A myostatin-targeting antibody tested alongside tirzepatide was well tolerated and, the authors conclude, effective at preserving lean mass. In its one trial, people on it lost 1.9 kg less lean mass than on placebo.

5 min read

MariTide (Maridebart Cafraglutide): What the Evidence Shows

Amgen's monthly MariTide cut weight 12.3% to 16.2% at 52 weeks in phase 2, against 2.5% on placebo. It blocks GIP where tirzepatide activates it. Side effects, the MARITIME phase 3 trials, and why it cannot be bought yet.

10 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Luvo Health

Moving between compounded and brand without changing seller

7.2

Oak

A choice of compounded injections, oral semaglutide and brand-name GLP-1s from one cash-pay checkout

6.4

MyDrHank

An oral route if you will not self-inject

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →